

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Link-Asia International MedTech Group Limited**

**環亞國際醫療科技集團有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1143)**

### **SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2022**

Reference is made to the annual report of Link-Asia International MedTech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2022 published on 28 April 2023 (the “**2022 Annual Report**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the 2022 Annual Report.

#### **FUNDRAISINGS**

Further to the information provided in the 2022 Annual Report, the Company would like to provide the shareholders of the Company and potential investors with the following supplemental information in relation to the use of proceeds of the fundraising activities below:

##### **Use of Proceeds from the Placing completed on 30 June 2021**

In the 2022 Annual Report, the Company disclosed on page 23 that the remaining unutilised net proceeds of approximately HK\$4.01 million from the placing that was completed on 30 June 2021 has not been fully utilised before 31 December 2022.

The intended use of the remaining unutilised net proceeds of approximately HK\$4.01 million was for purchasing inventories for developing the Group’s assisted reproduction medical technology business, however after communicating with the Group’s customers, the Group observes that there was reduced market demand for such inventories for the year ended 31 December 2022, therefore such remaining net proceeds have not been utilised as yet. The Group will continue to monitor the market demands, and it is expected that the remaining net proceeds will be utilized by 31 December 2023 if there is a strong demand in the market.

## Use of Proceeds from the Rights Issue completed on 23 November 2021

In the 2022 Annual Report, the Company disclosed on page 24 that the remaining net proceeds of HK\$17.1 million from the rights issue completed on 23 November 2021 which was intended for the funding of potential merger and acquisition opportunities of assisted reproductive services licensed providers located in regions in the PRC has not been utilized.

As the lock-down measures in the PRC have recently been lifted, the Group is still under the negotiations with the counterparty in relation to the terms of the potential merger and acquisition opportunities of assisted reproductive services licensed providers located in regions in the PRC. As at the date hereof, no terms have been agreed by the parties yet, hence the remaining net proceeds of HK\$17.1 million has not been utilized. It is expected that once the relevant terms in relation to such potential merger and acquisition have been finalized, the remaining net proceeds will be used as intended by 31 December 2023.

## SHARE OPTION SCHEME

Further to the information provided in the 2022 Annual Report, the Company would like to provide the shareholders of the Company and potential investors with the following supplemental information in relation to the share option scheme of the Company (the “**Share Option Scheme**”) pursuant to Rules 17.07(1)(d), 17.07(2), 17.07(3), 17.09(3), 17.07(3) and Rule 17.07A of the Listing Rules:

- (a) The weighted average closing price of the shares of the Company immediately before the dates on which share options were exercised during the year ended 31 December 2022 was HK\$1.06 per share.
- (b) As at 1 January 2022 and 31 December 2022, the total number of share options available for grant under the Share Option Scheme were 53,329,012 and 1,012 respectively.
- (c) The total number of Shares that may be issued in respect of options granted under all schemes of the Company during the year ended 31 December 2022 divided by the weighted average number of Shares in issue for the year ended 31 December 2022 was approximately 4.9%.
- (d) As at the date of the 2022 Annual Report, the total number of shares available for issue under the Share Option Scheme was 30,982,791, representing approximately 2.6% of the issued shares of the Company as at such date.
- (e) On 14 June 2022, 53,328,000 share options to subscribe for the ordinary shares of HK\$0.02 each in the share capital of the Company were granted to certain employees of the Group, subject to acceptance of the employees, under the share option scheme adopted by the Company on 10 March 2020.

## Summary of matters relating to the Scheme reviewed by the Remuneration Committee

### *Grant of share options under the Scheme*

Having considered that the past performance and contributions to the Group of the Grantees, the Remuneration Committee and the Board consider that the grant of such share options with a short vesting period:

- (i) aligns the interests of the Grantees with that of the Company and the shareholders of the Company as a whole;
- (ii) rewards and recognises the contribution of the Grantees to the Group; and
- (iii) provides incentive to the Grantees to continue to work for the success and improved performance of the Group. All of these are consistent with the purpose of the Scheme.

### *Performance target*

There is no performance target attached with the share options. The Remuneration Committee has noted that the purpose of the share option scheme is to provide incentive or reward to the Grantees for their contribution to the Group and that the share option scheme does not restrictively specify the contribution. The Remuneration Committee has also considered (a) the importance of the roles and responsibilities of the Grantees; (b) the past performance and contributions of the Grantees; and (c) the expected contributions of the Grantees to be made to the future development of the Group and is of the view that the grant of share options without any performance target aligns with the purpose of the share option scheme.

### *Clawback mechanism*

There is no clawback mechanism attached to the share options. The share options granted shall lapse and cannot be exercised with immediate effect if the Grantees, who is an employee (including any director), ceases to be an employee of the Group or a Director on the ground including, but without limitation to, that he or she has been guilty of serious misconduct.

In respect of the share options granted during the year ended 31 December 2022, the Remuneration Committee considers that the Scheme is intended to reward eligible participants who have contributed to the business development of the Group and to encourage eligible participants to work towards enhancing the value of the Company for the benefit of the Company and its shareholders as a whole. In addition, the Remuneration Committee also consider that: (a) the Grantees are eligible participants under the Scheme who would contribute directly to the overall business performance and sustainable development of the Group; (b) the granting of share options to the Grantees is a recognition for their past contributions to the Group; and (c) the share options are subject to the terms of the share option scheme which provides for circumstances under which the share options may lapse. Saved as disclosed above, the Company did not make any grant of share options to the directors and/or senior managers of the Group as set forth in Rules 17.03F, 17.06B(7) and 17.06B(8) of the Listing Rules during the year ended 31 December 2022.

The above addition information does not affect other information contained in the 2022 Annual Report. Save as disclosed above, all other information in the 2022 Annual Report remains unchanged.

On behalf of the Board  
**Link-Asia International MedTech Group Limited**  
**Lin Dailian**  
*Chairman and executive Director*

Hong Kong, 7 July 2023

*As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Liu Zhiwei, Mr. Li Yinxiang, Ms. Lin Xiaoshan and Ms. Bian Sulan as executive Directors; Mr. Li Huiwu and Mr. Chak Chi Shing as independent non-executive Directors.*